A Phase 3 interventional study of levetiracetam and placebo in Tardive Dyskinesia, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-06.
Sponsored by Yale University · Phase 3, Interventional, and Treatment
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
270 studies on the registry are indexed under Dyskinesias; 41 are open to participants now.
This study's enrollment of 50 is above the median of 44 across 192 interventional studies indexed under Dyskinesias.
Browse Dyskinesias studies →Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.
Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: meet Glazer Morgenstern criteria for TD -
Exclusion Criteria: none
-
Drug: levetiracetam
Drug: placebo
Abnormal Involuntary Movement Scale (AIMS) Total Score
Time frame: 12 weeks
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yale University